Immatics N.V. focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States.Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited.
